Drug Trial Radar · NCT06659263
RE104 Clinical Lactation Study
Last checked: Nov 19, 2026Latest source record: Jun 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Nov 13, 2024
Primary completion
May 28, 2025
Study completion Jun 4, 2025
Sponsor
- Lead sponsor
- Reunion Neuroscience IncIndustry
- Sponsor type
- Industry
- First posted
- Oct 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to obtain data necessary to characterize the elimination of RE104 and metabolites from breastmilk of health lactating volunteers to support a regulatory assessment of when mothers can safely return to breastfeeding following a single-dose of RE104 for Injection.
Conditions
- Lactation
Interventions
RE104 for InjectionDrug
Single, subcutaneous dose of RE104 for Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve from time zero to 24 hours post-dose (AUC0 24) for RE104 and 4-OH-DiPT in plasma and breast milkTime frame: Through 24 hours postdose
- Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for RE104 and 4-OH-DiPT in plasma and breast milkTime frame: Through 168 hours postdose
- Maximum observed concentration (Cmax) for RE104 and 4-OH-DiPT in plasma and breast milkTime frame: Through 168 hours postdose
- Time to reach Cmax (tmax) for RE104 and 4-OH-DiPT in plasma and breast milkTime frame: Through 168 hours postdose
- Apparent total body clearance (CL/F) for RE104 in plasmaTime frame: Through 168 hours postdose
- Apparent volume of distribution during the terminal phase (Vz/F) for RE104 in plasmaTime frame: Through 168 hours postdose
- Apparent terminal elimination half-life (t1/2) for RE104 and 4-OH-DiPT in plasmaTime frame: Through 168 hours postdose
- Milk to plasma (M/P) ratio for RE104 and 4-OH-DiPT in breast milkTime frame: Through 168 hours postdose
- Relative infant dose (RID) of RE104 and its active entity 4-OH-DiPTTime frame: Through 72 hours postdose
- Total RID of RE104 and its active entity 4-OH-DiPTTime frame: Through 168 hours postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD Inc
Las Vegas, Nevada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.